Industry News
AtCor files FDA application for cardiovascular monitor
AtCor Medical (ASX:ACG) has submitted an application for approval to market its updated SphygmoCor XCEL cardiovascular monitoring system in the US. [ + ]
Positive results from C-Pulse follow-up
Sunshine Heart (ASX:SHC) has released promising 12-month follow-up data from the feasibility trial for its C-Pulse Heart Assist System, as the trial heads into the two-year follow-up stage. [ + ]
Bioniche canine cancer product approved in NA
US and Canadian regulators have approved Immunocidin, the first of two canine cancer products developed by Bioniche (ASX:BNC). [ + ]
Future Fellowships funding supports Australia’s best mid-career researchers
The Minister for Science and Research, Senator Chris Evans, today announced 209 Future Fellowships totalling $151 million to provide research opportunities to some of the world’s best mid-career researchers. [ + ]
Putting smokers’ oxidative stress levels under the microscope
A new study investigating the effectiveness of live blood analysis (LBA) as a tool to measure oxidative stress is being conducted at Southern Cross University and smokers are being invited to take part. [ + ]
AusIndustry to hold registration workshops on Tax Incentive
AusIndustry is holding registration ready workshops to help companies better understand and register for the R&D Tax Incentive. [ + ]
Australia facing engineering shortage
Addressing the shortage of engineering skills in Australia will require targeted policies from the government to attract new engineers and retain existing engineers, according to a new report. [ + ]
pSivida gets FDA nod for phase III Medidur trial
The FDA has cleared pSivida (ASX:PVA) to jump straight to phase III trials of its micro-insert to deliver a posterior uveitis treatment, and to cite partner Alimera's data in its IND application. [ + ]
Narhex ex-CEO licenses HIV treatment for Mexico
Narhex (ASX:NLS) founder and former CEO John Majewski will form a new company to register and commercialise a HIV treatment developed under his watch in the Mexican market. [ + ]
Feature: Banking on nature
The Eskitis Institute’s Nature Bank holds a huge array of natural compounds for screening as potential drug leads, and researchers have invented a revolutionary new mass spectrometry tool to detect binding reactions with molecular targets. [ + ]
BioTek awarded patent for Hybrid Technology in multimode microplate readers
BioTek has been awarded US patent 8,218,141 covering the combination of two alternate paths for light within the same analytical instrument. [ + ]
$33 million supercomputer to support SKA science
A new $33 million supercomputer to be installed at the purpose-built Pawsey Centre in Perth will soon help scientists around Australia and the world to uncover the secrets of the universe. [ + ]
Iluvien on the march in Europe
pSivida (ASX:PVA) has had two wins this week for Iluvien, its treatment for vision impairment associated with chronic diabetic macular edema (DME). [ + ]
BioDiem partners with RMIT to extend vaccine technology
BioDiem (ASX:BDM) is looking to develop its vaccine technology to target indications beyond influenza through a research partnership with RMIT. [ + ]
Shimadzu UK focuses on molecular and atomic spectroscopy with new specialist recruit
Shimadzu UK is continuing its program of investment in the molecular and atomic spectroscopy markets by appointing Andy Winn as a Product Specialist for atomic absorption (AA), inductively coupled plasma (ICP) and total organic carbon (TOC) in the company’s Spectroscopy Group. [ + ]
